Ação de inseticidas sobre os ovos e lagartas da broca-pequena-dofruto do tomate, em bioensaio de laboratório / Action of insecticides on the eggs and larvae of the borer small-fruit tomato in laboratory bioassay

A broca-pequena-do-fruto é praga-chave na cultura do tomate por causar danos significativos às partes reprodutivas. Devido a isto, foi objetivo deste trabalho avaliar a eficiência de inseticidas sobre ovos e lagartas recém-emergidas, com e sem a adição de óleo vegetal (0,25%), em bioensaios de laboratório. Frutos com ovos foram coletados em cultivo de tomate estaqueado na quinzena posterior à última aplicação de agrotóxicos, sendo selecionados os frutos com ovos de coloração variável de branco a marrom claro, com 1 e 4 dias de incubação, e imersos em 1 L da calda inseticida por 5 segundos. O delineamento estatístico utilizado foi o inteiramente casualizado, com média de 18 frutos nos tratamentos e de, aproximadamente, 4 ovos/fruto. A avaliação da ação inseticida de 24 produtos foi realizada após a imersão na calda inseticida, observando-se, sob microscópio estereoscópico, os ovos quanto à integridade do córion, textura e coloração, lagartas emergidas, bem como os orifícios de entrada e de saída das larvas (aos 7 e 21 dias). Os produtos testados diferiram da testemunha quanto à densidade de lagartas eclodidas, bem como quanto à redução populacional de lagartas, podendo-se destacar Trebon 100 SC (etofenprox; 200 mL do produto comercial/100 L), Lannate BR (methomil; 100 mL), Thiobel 500 (cartap; 250 g) e Vertimec 18 CE (abamectin; 100 mL). A adição de óleo vegetal resultou em incremento na eficiência dos produtos.

Action of insecticides on tomato fruit borer eggs and larvae using laboratory bioassay. The tomato fruit borer is a key tomato pest in light of its damages to the plants’ reproductive parts. Therefore, the present study was aimed to evaluate the effectiveness of insecticides on the eggs and newly hatched larvae, when applied alone or associated with vegetable oil (0.25%), in laboratory bioassays. Fruits with eggs were collected in staked tomato crops fifteen days after the last application of agro-chemicals, selecting the fruits with eggs colored from white to light brown, which had between 1 and 4 days of incubation, followed by immersion of the fruit for 5 seconds in 1 L of the insecticide solutions. The experimental design was completely randomized, with an average of 18 fruits per treatment (24 insecticides and a control) and about 4 eggs per fruit. The evaluations were performed 7 and 21 days after immersion, using a stereomicroscope to observe the corion integrity, egg color, number of larvae emerged, and larvae fruit holes (entry and exit). The insecticides differed significantly from the control, most notably Trebon SC 100 (etofenprox; 200 mL of the commercial product/100 L), Lannate BR (methomil; 100 mL), Thiobel 500 (cartap; 250 g) and Vertimec 18 CE (abamectin; 100 mL). The addition of vegetable oil increased the insecticides’ effectiveness.

Clinical negligence, litigation and healthcare-associated infections.

BACKGROUND: Litigation costs resulting from clinical negligence claims involving healthcare-associated infections are a significant but underappreciated cost to healthcare organizations. In England these claims are handled on behalf of the National Health Service (NHS) organizations by the NHS Litigation Authority (NHSLA). The total number of claims and the amounts awarded have increased significantly in recent years. AIM: To determine whether the recent significant reductions in meticillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) and Clostridium difficile infections in England have had an effect on the number and value of NHSLA claims relating to these infections. METHODS: Data obtained from the NHSLA relating to claims mentioning C. difficile or MRSA from 2003 to 2010 were correlated with mandatory surveillance data from the Health Protection Agency for these infections. FINDINGS: The rate of NHSLA claims for MRSA has decreased in line with reductions in BSI for this infection (0.007 per BSI between 2003/4-2006/7 to 0.0017 per BSI between 2007/8 and 2010/11), but there was no significant change in claims relating to C. difficile infection. Overall the amounts awarded for successful claims have decreased significantly from a total of £76,846 for the period 1997/8-2006/7 to £24,821 for the period 2007/8-2010/11. CONCLUSIONS: The number of litigation claims involving MRSA has recently decreased significantly in line with surveillance data. There was no observed effect on claims involving C. difficile. The amounts awarded for successful claims for both infections have also fallen, although the reasons for this are not clear.

Treatment for pancreatic cancer.

Cancer of the pancreas is the fourth most common malignancy-induced cause of death in the United States. For patients with small primary tumors, surgery may produce long-term survival. However, because most patients are not diagnosed early, chemotherapy or radiation therapy may be beneficial. Combined modality therapies are under investigation and may prolong survival.

Symptom management for patients with pancreatic cancer.

Patients with pancreatic cancer have multiple symptoms from both disease and treatment. Pain, anorexia, nausea, vomiting, weight loss, fatigue, pruritus, and dyspnea are the most common symptoms. Until better treatments are found, patients with pancreatic cancer need effective symptom management to improve their quality of life.

Cancer of the prostate: treatment and nursing implications.

PURPOSE/OBJECTIVES: To review the clinical manifestations, current treatment, and nursing management of prostate cancer. DATA SOURCES: Published articles, book chapters, American Cancer Society booklets. DATA SYNTHESIS: Prostate cancer is a slow-growing malignancy and usually is asymptomatic in its early stages. It causes acute urinary obstruction at more advanced stages, and patients may present with metastatic disease. Diagnosis is made by biopsy, and treatment options include periodic observation, surgery, radiotherapy hormonal manipulation, and chemotherapy with standard or investigational drugs or combination therapy. The major complications associated with surgery and radiation therapy are transient or permanent incontinence and impotence. CONCLUSIONS: Because no definitive method for identifying clinically important lesions exists, much controversy surrounds prostate cancer treatment. Issues significant to the diagnosis and treatment of all stages of prostate cancer are identified, and nursing care concerns focusing on treatment and disease-related problems are presented. IMPLICATIONS FOR NURSING PRACTICE: Nursing care focuses on providing patients with accurate information to make informed decisions regarding treatment for early stage disease, on promoting comfort, and on preventing and managing treatment and disease-related complications. Nursing diagnoses include knowledge deficit; altered sexual patterns, body image disturbance, altered urinary elimination, diarrhea, impaired skin integrity, and pain, fatigue, bleeding, and infection, all of which are related to surgery, pathologic fractures, spinal cord compression, and edema of the scrotum/lower extremities.

Bladder preserving combined modality therapy for invasive bladder cancer.

The purpose of this paper is to increase the nurse's knowledge about invasive bladder cancer through discussion of a current protocol treatment using chemo and radiation therapy. Pathophysiology, clinical features, and current medical management are addressed along with appropriate nursing interventions, including symptom management and patient/family education. Research supports the observation that once patients complete the protocol regimen, the complete response rate is high and the need for radical surgery is low.